International Headache Society

    • Cephalalgia
    • The Neuroscientist
    • Cephalagia Reports
  • About IHS
  • Resources/Events
  • Membership
  • News
  • Learning Centre
  • Member Login
Home > 10-year cost-effectiveness analyses of fremanezumab compared to erenumab as preventive treatment in episodic migraine for patients with inadequate response to prior preventive treatments

Your privacy

We use cookies to improve your experience on our site and to show you personalised advertising.

To find out more, read our privacy policy and cookie policy.

Back to top
  • IHS Links
  • IHS Sponsors
  • IHS Privacy Policy
  • Contact the IHS
  • Facebook
  • Instagram
  • Twitter
  • LinkedIn
  • YouTube
International Headache Society, 6th Floor, 2 London Wall Place, London, EC2Y 5AU, United Kingdom. The International Headache Society is a UK registered charity.
Registered Charity Number: 1042574 ©2020 International Headache Society